Current status of new tuberculosis vaccine in children
Open Access
- 25 January 2016
- journal article
- review article
- Published by Informa UK Limited in Human Vaccines & Immunotherapeutics
- Vol. 12 (4), 960-970
- https://doi.org/10.1080/21645515.2015.1120393
Abstract
Pediatric tuberculosis contributes significantly to the burden of TB disease worldwide. In order to achieve the goal of eliminating TB by 2050, an effective TB vaccine is urgently needed to prevent TB transmission in children. BCG vaccination can protect children from the severe types of TB such as TB meningitis and miliary TB, while its efficacy against pediatric pulmonary TB ranged from no protection to very high protection. In recent decades, multiple new vaccine candidates have been developed, and shown encouraging safety and immunogenicity in the preclinical experiments. However, the limited data on protective efficacy in infants evaluated by clinical trials has been disappointing, an example being MVA85A. To date, no vaccine has been shown to be clinically safer and more effective than the presently licensed BCG vaccine. Hence, before a new vaccine is developed with more promising efficacy, we must reconsider how to better use the current BCG vaccine to maximize its effectiveness in children.Keywords
This publication has 99 references indexed in Scilit:
- Making wider use of the world's most widely used vaccine: Bacille Calmette–Guérin revaccination reconsideredJournal of The Royal Society Interface, 2013
- Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adultsVaccine, 2012
- Recombinant BCG ΔureC hly+ Induces Superior Protection Over Parental BCG by Stimulating a Balanced Combination of Type 1 and Type 17 Cytokine ResponsesThe Journal of Infectious Diseases, 2011
- Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: A phase III study in TanzaniaVaccine, 2010
- A Defined Tuberculosis Vaccine Candidate Boosts BCG and Protects Against Multidrug-Resistant Mycobacterium tuberculosisScience Translational Medicine, 2010
- Viral Booster Vaccines Improve Mycobacterium bovis BCG-Induced Protection against Bovine TuberculosisInfection and Immunity, 2009
- Delaying BCG vaccination from birth to 10 weeks of age may result in an enhanced memory CD4 T cell responseVaccine, 2009
- Immunization With a Bivalent Adenovirus-vectored Tuberculosis Vaccine Provides Markedly Improved Protection Over Its Monovalent Counterpart Against Pulmonary TuberculosisMolecular Therapy, 2009
- Protective Immune Responses to a Recombinant Adenovirus Type 35 Tuberculosis Vaccine in Two Mouse Strains: CD4 and CD8 T-Cell Epitope Mapping and Role of Gamma InterferonInfection and Immunity, 2007
- Intranasal Boosting with an Adenovirus-Vectored Vaccine Markedly Enhances Protection by Parenteral Mycobacterium bovis BCG Immunization against Pulmonary TuberculosisInfection and Immunity, 2006